Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

176.25 +0.26 (+0.15%)
Streaming Delayed Price Updated: 11:35 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
57 58 Next >
News headline image
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts ↗
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression. 
Via Benzinga
News headline image
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge ↗
 
Via Benzinga
News headline image
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? ↗
Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression. 
Via Benzinga
News headline image
Enduring Truths for Investors Both New and Seasoned ↗
Via The Motley Fool
News headline image
Peering Into Biogen's Recent Short Interest ↗
 
Via Benzinga
News headline image
17 Analysts Assess Biogen: What You Need To Know ↗
 
Via Benzinga
News headline image
Grid Expansion; Beaten Blues ↗
While the mega-caps seem to get all the attention these days, there's 1,000s of stocks out there worth researching. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected ↗
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025. 
Via Benzinga
News headline image
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. ↗
One analyst says the six-month study was too short and the benefits could appear over time. 
Via Investor's Business Daily
News headline image
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024 ↗
Via The Motley Fool
News headline image
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
News headline image
Assessing Biogen: Insights From 19 Financial Analysts ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Biogen Through Analyst Insights ↗
 
Via Benzinga
News headline image
Evaluating Biogen: Insights From 17 Financial Analysts ↗
 
Via Benzinga
News headline image
10 Worst Performing Large-Caps Last 12 Months ↗
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Large-Cap Stocks In Trouble - Saturday, Dec. 21 ↗
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
Topics Stocks / Equities
News headline image
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can xAI, Nvidia Help Stabilize Trajectory? ↗
Super Micro faces potential delisting from Nasdaq 100 Index due to underperformance and auditing scandal. Uncertainty surrounds its future. 
Via Benzinga
News headline image
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown ↗
Jefferies downgrades Biogen with a reduced price target, citing pipeline setbacks, slow Leqembi sales, and challenges from declining Ocrevus royalties. 
Via Benzinga
News headline image
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over ↗
Via The Motley Fool
News headline image
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside ↗
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. 
Via Benzinga
News headline image
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 ↗
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show gradual growth amid market challenges. 
Via Benzinga
News headline image
This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>